Navigation Links
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:6/26/2009

n's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Centocor Ortho Biotech Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.)

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" wi
'/>"/>

SOURCE Schering-Plough Corporation; Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
2. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
3. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
4. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
5. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
6. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
7. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
8. AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
9. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
10. Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma
11. Pelleve Receives FDA Clearance for the Treatment of Mild to Moderate Facial Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... LYNBROOK, N.Y. , Sept. 19, 2014  BioSpecifics Technologies ... first in class collagenase-based products marketed as XIAFLEX ® ... announced today that BioSpecifics, President, Tom Wegman , will ... BioCentury NewsMakers in the Biotech Industry Conference. ... at 3:00 p.m. EDT at the Millennium Broadway Hotel in ...
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia Therapeutics, ... clinical data for its lead candidate ITCA 650 (continuous ... with high baseline HbA1c levels at the 50 th ... Study of Diabetes (EASD). Data from the open-label, phase ... of blood sugar in patients with poorly controlled type ...
(Date:9/19/2014)... 19, 2014  PCI is pleased to announce ... is a leading provider of Clinical Trial Services ... Wales in the ... expands PCI,s presence in the UK/EU to support ... packaging, storage and distribution capacity, as well as ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
... NEW YORK, Jan. 10, 2012  ( http://www.myprgenie.com/  ) ... Americans 10 years ago and ask them where they found ... their current healthcare provider in their insurance plan directory or ... that is not the case.  Eighty percent of all U.S. ...
... uVera Diagnostics has introduced the CR3 Keyless Split Sample Cup ... cup provides several state-of-the-art features not available together in any ... to the drug testing industry," said Rick Nee, president of ... of use for both genders. The unique patented device is ...
Cached Medicine Technology:Castle Connolly Makes Finding the Best Healthcare from Top Doctors Even Easier 2uVera Diagnostics Offers New Drug Screening Product 2
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... Majidi, M.D., a second-year resident in the Department ... of Medicine and Health Sciences, received at $154K ... the presence of diffuse brain swelling and injury ... to epidemiological studies, intracerebral hemorrhage accounts for less ... the least treatable form of stroke, with the ...
(Date:9/19/2014)... BCC Research reveals in its new ... , the global market for human antifungal therapeutics is ... with a five-year compound annual growth rate (CAGR) of ... a steady 3.8% CAGR. , Given the current world ... with the incidence of increasing mortality and the severity ...
(Date:9/19/2014)... Dallas, Texas (PRWEB) September 19, 2014 ... blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 ... released from a variety of cells, including mast cells ... CysLT receptors. Several studies have determined that there are ... of asthmatics compared with non-asthmatic individuals. The production of ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... agents, an integral part of the medical imaging market, ... organs. Effervescent technology developments over the past three decades ... medical diagnostics. From barium and iodine based agents used ... as gold nanoparticles and radiopharmaceuticals, imaging agents have witnessed ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:GW researcher receives grant to study brain swelling following bleeding in the brain 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 2Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 3Health News:Singulair Asthma Market to 2023 – Etiology, Pathophysiology, Diagnosis & Treatment Overview in New Report Available at LifeScienceIndustryResearch.com 4Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4
... Aug. 13 As reported in publications and news,outlets ... "buck" teeth was replaced at the summer games opening ... the decision spawned,disbelief around the globe, sadly, the phenomenon ... of their teeth is nothing new., In a ...
... donations for breast cancer,research/programs, DETROIT, Aug. 13 ... part to end cancer, as well as honor the ... goal of walking 18,marathons in 18 days -- The ... cancer research and programs at the Barbara Ann Karmanos ...
... 3 new reports raise question of how long a heart ... 13 (HealthDay News) -- Three new reports challenge current guidelines ... taking a heart from an infant organ donor. , There,s ... no question that there aren,t enough donor organs to save ...
... Weiner Says Calls for,Privatization and ,Reform, are Granny-on-Your-Own, ... WASHINGTON, Aug. 13 On Social Security,s,73rd Anniversary ... of Staff,Robert Weiner is saying, "Calls to ,reform, ... Street,giveaway which would turn Social Security from a ...
... Held Thursday, August 14, 2008 at 9:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reports operational and,financial results ... year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "Alseres made solid ...
... -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... Republic of China,("PRC"), today announced that it will ... on Monday, August 18, 2008 to discuss results ... Dr. Zhongyi Liu, Chairman and Chief Executive Officer ...
Cached Medicine News:Health News:Summer Games 'Swap' Raises Questions About Image, Oral Health 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:Infant Heart Transplant Controversy Continues 2Health News:Infant Heart Transplant Controversy Continues 3Health News:Infant Heart Transplant Controversy Continues 4Health News:Social Security's 73rd Anniversary 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 2Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 3Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 4Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 5Health News:Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results 6Health News:Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results 2
... Volks revolutionary MiniQuad, the DynaView 156 is ... of the retina extending to the ora ... patients. Featuring a minified housing and reduced ... revolutionizes retinopathy of prematurity surgery and is ...
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... re-designed Super Macula® 2.2 offers extremely high ... fovea, while achieving an exceptionally wide 78° ... excellent choice for critical evaluation of the ... for detailed views of the macula and ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
Medicine Products: